American Association for Cancer Research
23266066cir140165-sup-137431_1_supp_2813650_nhv45r.png (226.29 kB)

Supplementary Figure 2 from Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141+ Dendritic Cells and Enhanced Cross-Presentation

Download (226.29 kB)
posted on 2023-04-03, 23:12 authored by Berbel J.R. Sluijter, Mari F.C.M. van den Hout, Bas D. Koster, Paul A.M. van Leeuwen, Famke L. Schneiders, Rieneke van de Ven, Barbara G. Molenkamp, Saskia Vosslamber, Cornelis L. Verweij, M. Petrousjka van den Tol, Alfons J.M. van den Eertwegh, Rik J. Scheper, Tanja D. de Gruijl

Expression of the cross-priming associated markers BDCA3/CD141 and CLEC9A on the four identified cDC subsets in single-cell suspensions of untreated melanoma Sentinel Lymph Nodes SLN (mean {plus minus} SEM of at least three separate experiments are shown).



Melanoma-induced suppression of dendritic cells (DC) in the sentinel lymph node (SLN) interferes with the generation of protective antitumor immunity. In an effort to strengthen immune defense against metastatic spread, we performed a three-arm phase II study comprising 28 patients with stage I–II melanoma randomized to receive intradermal injections around the primary tumor excision site of saline or low-dose CpG-B, alone or combined with GM-CSF, before excision of the SLNs. After pathologic examination, 5 patients were diagnosed with stage III melanoma based on the presence of tumor cells in the SLNs. Combined CpG/GM-CSF administration resulted in enhanced maturation of all identifiable conventional (cDC) and plasmacytoid (pDC) DC subsets and selectively induced increased frequencies of SLN-resident BDCA3/CD141+ cDC subsets that also expressed the C-type lectin receptor CLEC9A. Correlative in vivo analyses and in vitro studies provided evidence that these subsets were derived from BDCA3+ cDC precursors in the blood that were recruited to the SLNs in a type I IFN-dependent manner and subsequently matured under the combined influence of CpG and GM-CSF. In line with their reported functional abilities, frequencies of in vivo CpG/GM-CSF–induced BDCA3/CD141+ DCs correlated with increased ex vivo cross-presenting capacity of SLN suspensions. Combined local CpG/GM-CSF delivery thus supports protective antimelanoma immunity through concerted activation of pDC and cDC subsets and recruitment of BDCA3+ cDC subsets with T cell–stimulatory and cross-priming abilities. Cancer Immunol Res; 3(5); 495–505. ©2015 AACR.

Usage metrics

    Cancer Immunology Research



    Ref. manager